How Wegovy Helps the Heart — and What the Evidence Actually Shows

The misconception worth clearing up first

Most people asking how Wegovy helps the heart assume the answer is straightforward: you lose weight, your heart works less hard, job done. That is not wrong, but it is incomplete. The SELECT trial enrolled adults who were already taking statins or other cardiac medicines, had a BMI of 27 or above, and had a prior heart attack or stroke, but deliberately excluded anyone with type 2 diabetes. The weight loss in that group was meaningful but not dramatic. Yet semaglutide still cut the combined risk of cardiovascular death, non-fatal heart attack and non-fatal stroke by around 20% compared with placebo over a median follow-up of about 33 months.

That result holds even after adjusting for the weight change. So while losing weight is genuinely good for the heart, the medicine appears to bring something extra. Researchers are still working out exactly what, possibilities include reduced systemic inflammation, direct effects on arterial wall function, modest falls in blood pressure and improvements in lipid profiles. None of that is fully settled science yet, but the clinical outcome data, published in the SELECT trial in the New England Journal of Medicine, is robust enough that the MHRA granted a separate UK licence for this indication. For anyone wanting to explore how Wegovy helps heart health alongside the weight-management evidence, our Wegovy overview page covers both.

Which patients the cardiovascular licence actually covers

The UK cardiovascular authorisation is specific. It applies to adults aged 45 and over with BMI 27 or above who have established cardiovascular disease, meaning a previous heart attack, stroke or peripheral arterial disease. It does not cover people who simply have risk factors such as high blood pressure or a family history. It does not cover type 2 diabetes (that is Ozempic's territory). And it does not automatically apply to everyone who qualifies for Wegovy for weight management under the standard BMI criteria.

This matters practically. A person with a BMI of 31 and no prior cardiac events is eligible for the weight-management indication but not the cardiovascular one. A person with a BMI of 28 who had a heart attack two years ago may qualify under the cardiovascular licence even though their BMI sits below the standard weight-management threshold. The two licences are complementary, not interchangeable. If you want to understand whether the cardiovascular indication is relevant to your situation, a prescriber needs to assess your full medical history, a question our clinical team handles as part of every consultation.

It is also worth knowing that the MHRA approved Wegovy for a form of liver disease (MASH) in July 2026, a further sign that semaglutide's benefits extend across several systems, though that liver indication is a separate topic.

How semaglutide acts on the cardiovascular system

GLP-1 receptors are not confined to the gut and pancreas. They are present in the heart muscle itself, in the blood vessel walls and in parts of the brain that regulate vascular tone. When semaglutide activates these receptors, it appears to reduce inflammation markers, improve endothelial function (the responsiveness of artery linings), and modestly lower both systolic blood pressure and LDL cholesterol. None of these effects is large enough on its own to explain a 20% reduction in hard cardiovascular outcomes, but together they likely contribute alongside the metabolic benefits of weight loss.

Resting heart rate tends to rise slightly with GLP-1 medicines (a well-documented and generally benign effect) so the cardiovascular picture is not uniformly favourable at every level. Anyone with a history of arrhythmia or certain heart conditions should discuss this specifically with their prescriber. The NHS semaglutide page lists the side effects and interactions relevant to cardiac patients in plain terms. For a broader look at the relationship between this medicine and heart health, our page on Wegovy and the heart goes deeper.

Practical implications if cardiovascular risk is part of your picture

If you have existing heart disease and are considering semaglutide, the conversation with your prescriber should cover a few things beyond the standard eligibility check. Your current cardiac medicines matter: Wegovy can affect how quickly other drugs are absorbed because it slows gastric emptying, so timing of other medicines may need reviewing. If you take anticoagulants or antiplatelet drugs, that is worth flagging. The cost of private Wegovy treatment is a real consideration too, given that NHS access for the cardiovascular indication is still limited outside specialist services.

Blood pressure often falls as weight comes off, which is welcome but can occasionally require adjustment of antihypertensive doses, another reason why ongoing clinical review matters, not just a one-off prescription. At nume, every repeat order is reviewed by a prescriber before dispatch; there are no auto-renewals. Some patients also ask whether semaglutide influences alcohol cravings, and our page on whether Wegovy helps you stop drinking looks at what the emerging evidence suggests. If you have questions about type 2 diabetes alongside cardiac risk, our page on Wegovy and type 2 diabetes addresses the overlap. And if you are ready to discuss whether treatment is right for your situation, check your eligibility with our prescribers at no cost.